



May 9, 2023

Dear Colleague,

The Centers for Disease Control and Prevention (CDC) recently revised the mRNA COVID-19 vaccination schedule for people who are moderately or severely immunocompromised. The changes are now reflected in [CDC’s Interim Clinical Considerations](#) and follow other changes to the COVID-19 vaccination schedule that were shared with NYC providers in [April](#).

Guidance for people who are moderately or severely immunocompromised is as follows:

- People who are receiving their **initial COVID-19 vaccination** are **recommended** to receive **3 bivalent mRNA doses**.
- People who **previously received only monovalent doses** are **recommended** to receive **1 or 2 bivalent mRNA vaccine doses**, depending on vaccination history.
- People who **previously received a bivalent mRNA vaccine dose** have the **option** to receive **1 additional bivalent mRNA** dose at least two months after their prior bivalent dose; further additional bivalent doses may be administered at the discretion of their healthcare provider.

Detailed tables of the revised schedules for people who are immunocompromised are posted [here](#). The tables are organized by age and COVID-19 vaccination history.

Note that the Emergency Use Authorizations for [Moderna](#) and [Pfizer](#) COVID-19 vaccines allow flexibility for use of vaccine products, number of doses, and dosage, based on individual circumstances and clinical judgement.

We also want to highlight that there are currently two different Moderna bivalent products that can be given to children ages 6 months through 5 years. We know this is confusing.

Always consult the vaccination schedules in [CDC’s Interim Clinical Considerations](#) if you are unsure of which product or dosage to use.

Moderna product and dosage	Recommended usage for children ages 6 months through 5 years who are NOT moderately or severely immunocompromised	Recommended usage for children ages 6 month through 5 years who ARE moderately or severely immunocompromised
Dark blue cap and gray label border 0.25 ml/25 mcg	<ul style="list-style-type: none"> • Doses 1 and 2 in children who are receiving their initial COVID-19 vaccination • Dose 2 in children who previously received 1 dose of monovalent Moderna vaccine 	<ul style="list-style-type: none"> • Doses 1, 2, and 3 in children who are receiving their initial COVID-19 vaccination • Dose 4 in children <u>age 5 years only</u> who previously received 3 doses of monovalent Moderna vaccine

Dark pink cap and yellow label border 0.2 ml/10 mcg	<ul style="list-style-type: none"> • Dose 3 in children who previously received 2 monovalent doses of Moderna vaccine 	<ul style="list-style-type: none"> • Dose 4 in children <u>ages 6 months to 4 years</u> who previously received 3 monovalent doses of Moderna vaccine • Optional additional dose(s)
---	--	---


All providers administering Moderna COVID-19 vaccine to children ages 6 months through 5 years should have both products on hand (dark blue cap and gray label border + dark pink cap and yellow label border). Providers enrolled in the COVID-19 vaccination program can order vaccines in the [CIR Online Registry](#).

COVID-19 vaccination is now part of the [routine immunization schedules](#) from the Advisory Committee on Immunization Practice. Providers who are not yet enrolled in the COVID-19 vaccination program are encouraged to do so, so they can order and administer COVID-19 vaccine at their practices and facilities.

If you are unable to order and administer COVID-19 vaccine, refer patients to a vaccination site. To find a vaccination site, visit vaccinefinder.nyc.gov.

Thank you for continuing to protect the health of New Yorkers.

Sincerely,



Jane R. Zucker, MD, MSc
Assistant Commissioner
Bureau of Immunization
New York City Department of Health and Mental Hygiene